C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $582,324 | -12.1% | 313,077 | +29.9% | 0.00% | – |
| Q2 2023 | $662,858 | -28.2% | 241,039 | -18.1% | 0.00% | – |
| Q1 2023 | $923,594 | -58.7% | 294,138 | -22.4% | 0.00% | – |
| Q4 2022 | $2,237,275 | -25.9% | 379,199 | +10.1% | 0.00% | – |
| Q3 2022 | $3,019,000 | -12.1% | 344,387 | -24.4% | 0.00% | – |
| Q2 2022 | $3,434,000 | -78.5% | 455,456 | -30.7% | 0.00% | -100.0% |
| Q1 2022 | $15,954,000 | -46.1% | 657,572 | -28.4% | 0.00% | -50.0% |
| Q4 2021 | $29,575,000 | +128.2% | 918,470 | +216.6% | 0.00% | +100.0% |
| Q3 2021 | $12,961,000 | +24.0% | 290,096 | +5.0% | 0.00% | +100.0% |
| Q2 2021 | $10,451,000 | +1233.0% | 276,188 | +1203.1% | 0.00% | – |
| Q1 2021 | $784,000 | +159.6% | 21,195 | +132.7% | 0.00% | – |
| Q4 2020 | $302,000 | – | 9,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $21,495,000 | 5.67% |
| Soleus Capital Management, L.P. | 750,633 | $33,538,000 | 5.23% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $73,374,000 | 4.55% |
| RTW INVESTMENTS, LP | 2,494,965 | $111,475,000 | 1.68% |
| P.A.W. CAPITAL CORP | 40,000 | $1,787,000 | 1.59% |
| Perceptive Advisors | 2,258,566 | $100,913,000 | 1.47% |
| SPHERA FUNDS MANAGEMENT LTD. | 381,774 | $17,058,000 | 1.43% |
| CLOUGH CAPITAL PARTNERS L P | 347,500 | $15,526,000 | 0.94% |
| HighVista Strategies LLC | 29,341 | $1,311,000 | 0.87% |
| RA Capital Management | 1,377,569 | $61,550,000 | 0.85% |